NASDAQ Soins de santé Biotechnologie LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

$ 0.39 -35.89 %

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

CEO: Kelvin Cooper - http://www.lakewoodamedex.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

-

Recommandation

-

DCF

$ -

Loading data...

LABT vs S&P500

Loading data...

No data available.

Quick ratio

0

P/E ratio

0.00

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

0 %

ROIC

0 %

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-

Free cash flow per share

0

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0 %

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
N/A
Altman score
N/A
Loading data...

No data available.

Cash / Debt

Cash Ratio
Debt Ratio
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.